Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ravidasvir

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 69Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Malaysia set to become Hepatitis C treatment hub of Asia
    Malaysia set to become Hepatitis C treatment hub of Asia

    16 Nov 2021

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/30/19355/malaysia-set-to-become-hepatitis-c-treatment-hub-of-asia.html

    BIOSPECTRUMASIA
    16 Nov 2021
    Share Share
    Ascletis' All-oral HCV Treatment Approved for Marketing in China
    Ascletis' All-oral HCV Treatment Approved for Marketing in China

    31 Jul 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-all-oral-hcv-treatment-approved-for-marketing-in-china-301103622.html

    PRNEWSWIRE
    31 Jul 2020
    Share Share
    WHO HCV Guidelines recommends Ascletis' Ravidasvir
    WHO HCV Guidelines recommends Ascletis' Ravidasvir

    09 Aug 2018

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/25/11475/who-hcv-guidelines-recommends-ascletis-ravidasvir.html

    BIOSPECTRUM
    09 Aug 2018
    Share Share
    Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA
    Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

    02 Aug 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-nda-for-its-all-oral-hcv-treatment-accepted-by-cfda-300690036.html

    PR NEWSWIRE
    02 Aug 2018
    Share Share
    Making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO
    Making Hong Kong history, Ascletis eyes $457M haul in GIC-backed IPO

    18 Jul 2018

    // Amber Tong ENDPTS

    https://endpts.com/on-its-way-to-making-hong-kong-history-ascletis-eyes-457m-haul-in-gic-backed-ipo/

    Amber Tong ENDPTS
    18 Jul 2018
    Share Share
    Epclusa's fast-tracked Chinese approval might be late for Gilead
    Epclusa's fast-tracked Chinese approval might be late for Gilead

    31 May 2018

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded

    Angus Liu FIERCE PHARMA
    31 May 2018
    Share Share